A better understanding of the genomics of this malignancy, as well as improved imaging techniques and developments of new therapeutics, is pushing the evolution of the diagnosis and treatment of advanced prostate cancer.
Two placebo-controlled trials found that treatment of nonmetastatic castration-resistant prostate cancer with androgen signaling inhibitors (ASIs) delays the development of metastatic disease and may prolong survival.
Dr. Christian Kollmannsberger, a medical oncologist with the British Columbia Cancer Centre and clinical professor at the University of British Columbia, will discuss management of stage II testicular cancer during his keynote lecture,
Dr. Robert J. Motzer will discuss the development and approval of tyrosine-kinase inhibitors (TKIs) for renal cell carcinoma (RCC) during his keynote lecture on February 10, touching on pivotal trials and controversies.
Dr. Seth P. Lerner, the Beth and Dave Swalm Chair in Urologic Oncology at Baylor College of Medicine, will discuss the impact of The Cancer Genome Atlas on bladder cancer research and the oncology field as a whole during his keynote lecture on February 9.
The ASCO MOC app allows easy access to self-assessment questions designed for your mobile device, as well as courses that offer an engaging technique to help oncologists retain information with a pulsed-education approach.
ASCO has issued the “ASCO Position Statement on Addressing the Affordability of Cancer Drugs” to contribute to the national dialogue on rising cancer drug prices, asserting that any solutions must also preserve patients’ access to care and foster innovation.
ASCO's TAPUR Study continues to expand and now has more than 450 participants enrolled on study drug, new partnerships, and a revised protocol to lower the age of eligibility, and will soon have more than 100 sites.
The phase III PROSELICA study, which assessed the noninferiority of cabazitaxel 20 mg/m2 versus C25 in post-docetaxel patients with mCRPC, confirmed the activity of cabazitaxel and demonstrated that a dose reduction retains significant clinical benefits for these patients.
Dr. William W. Mayo-Smith, vice chair of radiology at Brigham & Women’s Hospital and professor of radiology at Harvard Medical School, will review methods for detecting and diagnosing adrenocortical carcinomas in his keynote presentation.
Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit.